Johnson & Johnson announced that its drug Tremfya significantly improved spinal pain and stiffness in adults with axial psoriatic arthritis in a Phase 4 clinical trial. The STAR study showed Tremfya outperformed placebo in reducing disease activity and inflammation in the spine and sacroiliac joints, confirmed by MRI. This is the first trial to evaluate an IL-23 inhibitor specifically for axial involvement in psoriatic arthritis. The study is ongoing, with full results expected by April 2027, and no new safety concerns were reported so far.
As of Sep 25, 2026 21:41 WIB, Johnson & Johnson (JNJ) shares are priced at USD 270.55 on Pluang, showing a slight 0.05% decrease in the last day. The stock has a market cap of $652.31 billion and an enterprise value of $680.59 billion. Despite the recent clinical trial news, the Pluang order activity leans heavily toward selling at 85%.
AbbVie and Johnson & Johnson are both strong dividend stocks trading near their 52-week highs, but they differ significantly in risk and growth. AbbVie shows faster revenue growth and a higher dividend yield, driven by its immunology drugs, but faces...
Johnson & Johnson announced that TREMFYA (guselkumab) met primary and major secondary endpoints in the Phase 4 STAR study, showing significant improvement in axial symptoms and MRI-confirmed inflammation in biologic-naïve adults with active psoriatic...
Johnson & Johnson announced long-term results from the Phase 2 CARTITUDE-2 study showing that 50% of multiple myeloma patients treated early with a single CARVYKTI infusion remained alive and progression-free for at least five years without maintenan...
Retirees deciding between federally insured CDs and dividend stocks must consider yield stability versus growth potential. CDs offer fixed interest rates, currently averaging 1.73% nationally, with FDIC insurance protecting principal up to $250,000. ...
Johnson & Johnson announced data from the Phase 3 MajesTEC-3 trial showing that combining TECVAYLI with DARZALEX FASPRO significantly improves survival in relapsed or refractory multiple myeloma patients. About 87% of treated patients had mortality r...
